Predictors of response to interferon therapy

Current Opinion in Oncology

Volumn 21, Issue 2, 2009, Pages 138-143

  Gogas, Helen ^a,c   Kirkwood, John M ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c NONE   (Greece)

Author keywords

Adjuvant therapy; Interferon alfa; Melanoma; Predictive factors

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; INTERFERON; PEGINTERFERON ALPHA2B;

ANTINEOPLASTIC ACTIVITY; CANCER RECURRENCE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG USE; HUMAN; MELANOMA; PREDICTION; PRIORITY JOURNAL; REVIEW; ULCERATED MELANOMA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; INTERFERONS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 62349106907     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328325317a     Document Type: Review

References (38)

1. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
2. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18:2444-2458.
3. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19:2370-2380.
4. Cascinelli N, Bufalino R, Morabito A, MacKie R. Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994; 343:913-914.
5. Cascinelly N, Belli F, MacKie RM, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomized trial. Lancet 2001; 358:866-869.
6. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research Randomized Study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004; 22:53-61.
7. Eggermont AMM, Suciu S, Macki R, et al. Postsurgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomized controlled trial. Lancet 2005; 366:1189-1196.
8. Eggermont AMM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomized phase III trial. Lancet 2008; 372:117-126. Patients with N1 microscopic nodal involvement (sentinel node positive) experienced greater benefit in terms of both RFS and distant metastasis-free survival. A better effect of adjuvant IFN therapy in patients with lower disease burden has also been observed in EORTC 18952 trial (1388 patients) so this is consistent outcome in 2644 randomized patients.
9. Kirkwood J. Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 2002; 29:18-26.
10. Mihm MC Jr, Clemente CG, Cascineli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996; 74:43-47.
11. Hakansson A, Gustafsson B, Krysander I, Hakansson I. Tumor-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 1996; 74:670-676s.
12. Hakansson A, Gustafsson B, Krysander L, et al. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J Interferon Cytokine Res 1998; 18:33-39.
13. Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage IHB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006; 24:3164-3171.
14. Pestka S. The interferon receptors. Semin Oncol 1997; 24:S9-S40.
15. Lesinski GB, Anghelina M, Zimmerer J, et al. The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest 2003; 112: 170-180.
16. Wang W, Edington HD, Rao UN, et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFN (alpha)2b. Clin Cancer Res 2007; 13:1523-1531. The pSTAT1/pSTAT3 ratio in tumor cells at baseline may serve as a useful predictor of clinical outcome in cutaneous melanoma; the modulation of this ratio may serve as a predictor of therapeutic effect. This warrants further evaluation in larger patient samples as a potential prognostic and predictive index of disease.
17. Kirkwood JM, Richards T, Zarour H, et al. Immunomodulatory effects of high-dose and low-dose interferon a2b in patients with high-risk resected melanoma. The2690 laboratory corollary of Intergroup Adjuvant Trial E1690. Cancer 2002; 95:1101-1112.
18. Yurkovetsky ZR, Kirkwood JM, Edington HD, et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-a2b. Clin Cancer Res 2007; 13:2422-2428. A multiplexed analysis of serum biomarkers is useful for the evaluation of prognostic markers of clinical outcome and potential predictive markers of response to IFN-a2b in patients with high-risk operable melanoma.
19. Atkins MB, Mier JW, Parkinson DP, et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-acivated killer cells. N Engl J Med 1988; 318: 1557-1562.
20. Weijl NI, Van Der Harst D, Brand A, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 1993; 11:1376-1383.
21. Scalzo S, Gengaro A, Boccoli G, et al. Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. Eur J Cancer 1990; 26:1152-1156.
22. Krouse RS, Royal RE, Heywood G, et al. Thyroid dysfunction in 281 patients with metastatic melanoma in renal carcinoma treated with interleukin-2 alone. J Immunother Emphasis Tumor Immunol 1995; 18:272-278.
23. Phan GQ, Attia P, Steinbrg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19:477-3482.
24. Becker JC, Winkler B, Klingert S, et al. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 1994; 73:1621-1624.
25. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 1996; 19:81-84.
26. Gogas H, loannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with Interferon. N Engl J Med 2006; 354:709-718.
27. Dafni U, Pectasides D, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. Updated follow-up [abstract #9024]. Proc ASCO 2008; 26:488s. The detection of autoantibodies and the appearance of clinical manifestations of autoimmunity remain a significant prognostic marker for RFS and OS with additional follow-up.
28. Stuckert JJ II, Tarhini AA, Lee S, et al. Inteferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high risk melanoma in the ECOG-intergroup phase II trial E2696 [abstract 8506]. Proc ASCO 2007; 25:473s.
29. Bouwhuis M, Suciu S, Kruit W, et al. Prognostic value of autoantibodies (auto-AB) in melanoma patients (pts) in the EORTC 18952 trial of adjuvant interferon (IFN) compared to obsesrvation (obs) [abstract 85071. Proc ASCO 2007; 25:473s.
30. Shiina T, Iniko H, Kulski JK. An update of the HLA genomic region, locus information and disease associations: 2004. Tissue Antigens 2004; 64:631-649.
31. Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases: a general susceptibility gene to autoimmunity? Genes Immun 2000; 1:170-184.
32. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997; 7:445-450.
33. Bennet L, Christie J, Ransdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27:21-31.
34. Hori S, Nomura T, Sakaquchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-1061.
35. Gogas H. Perspectives in melanoma XII, The Hague, The Netherlands, 2-4 October 2008. The presence of HLA-Cw*06 allele was related with better RFS and OS and the appearance of autoimmunity. The allele Cw*06 has been correlated with psoriasis. These results if validated in trials of adjuvant IFN conducted in separate US and European Cooperative groups could be used to identify patients who would benefit from adjuvant IFN.
36. Brunet JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin super-family: CTLA-4. Nature 1987; 328:267-270.
37. Ueda H, Howson JMM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-511.
38. Gogas H, Metaxas Y, Dafni U, et al. Evaluation of CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant Interferon [abstract #9054]. Proc ASCO 2008; 26:496s.